Tamer Mohamed

Institute of Molecular Cardiology, Department of Medicine

University of Louisville

Tamer M.A. Mohamed
Assistant Professor

During my research endeavors, I have studied novel mechanisms and therapies for cardiac hypertrophy and heart failure. My research in the recent years had major impact on two approaches for endogenous heart repair: direct cardiac reprogramming and inducing cardiomyocyte proliferation. Both approaches were highly successful. Direct reprogramming approach was the nucleus for an emerging start-up (Tenaya Therapeutics) where I was the first scientist recruited to the company to lead the efforts of direct cardiac reprogramming. Where I enjoyed the unique industry experience in building a start up from scratch. Due to the quick success in Tenaya, which just raised ~$100 million to start clinical trials, the research and development section ended very soon and now the major focus on scaling up viral manufacturing and filing IND which is away from my interest. Therefore, I have decided to go back to academia to initiate new discovery programs for heart failure therapy mainly focusing on understanding the regulation of cardiomyocyte proliferation. Most recently, my laboratory established a novel system for long term culture of human and pig heart slices and efficiently demonstrating the efficacy of direct cardiac reprogramming in such pre-clinical models (Ou et al., Circulation Research, 2019).


Slicing and Culturing Pig Hearts under Physiological Conditions

1Institute of Molecular Cardiology, Department of Medicine, University of Louisville, 2Department of Bioengineering, University of Louisville, 3Diabetes and Obesity Center, Department of Medicine, University of Louisville, 4Department of Pharmacology and Toxicology, University of Louisville, 5Institute of Cardiovascular Sciences, University of Manchester, 6Faculty of Pharmacy, Zagazig University

JoVE 60913